GemPharmatech (SH:688046) Shang Hai Zheng Quan Bao·2026-01-07 18:19Core Viewpoint - Jiangsu Jicui Yaokang Biotechnology Co., Ltd. (referred to as "Yaokang Bio") is partially exiting its investment in Jiangxi Zhonghong Boyuan Biotechnology Co., Ltd. through a directed capital reduction, returning an investment of RMB 10 million and receiving a corresponding compensation for fund occupation at an annual interest rate of 5% [2][3]. Summary by Sections 1. Overview of Related Transactions - As of the announcement date, Yaokang Bio has invested RMB 70 million in Jiangxi Zhonghong, holding 22.8261% of its shares. The company will reduce its investment through a directed capital reduction, receiving RMB 10 million back and adjusting its shareholding to 20.2247% [4][10]. - If Jiangxi Zhonghong agrees to allow other shareholders to also reduce their investments by a total of RMB 15 million, Yaokang Bio's shareholding will adjust to 20.9302% [4][10]. 2. Related Party Information - Jiangxi Zhonghong is classified as a related party due to Yaokang Bio's shareholding [6]. 3. Transaction Pricing - The historical total investment by Yaokang Bio is RMB 70 million, and the capital reduction of RMB 10 million corresponds to a shareholding reduction of 2.6014% [10]. - The compensation for fund occupation is calculated to be RMB 1,657,534.25, based on the formula provided [10][12]. 4. Necessity and Impact of the Transaction - The transaction aligns with the overall development strategy and operational plans of the company, and it is not expected to negatively impact the financial status or operational results of Yaokang Bio [21]. 5. Review Procedures - The independent directors and the audit committee have approved the transaction, confirming that the pricing is fair and does not harm the interests of other shareholders [22][23][24].